{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:22:48Z","timestamp":1778682168186,"version":"3.51.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11096-025-01932-0","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T09:57:21Z","timestamp":1751450241000},"page":"1365-1374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["RETRACTED ARTICLE: Real-world data and Mendelian randomization analysis in assessing adverse reactions of rilonacept"],"prefix":"10.1007","volume":"47","author":[{"given":"Lihong","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenfei","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"1932_CR1","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.108.844753","volume":"121","author":"M Imazio","year":"2010","unstructured":"Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation. 2010;121:916\u201328.","journal-title":"Circulation"},{"key":"1932_CR2","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMc1315653","volume":"370","author":"M Imazio","year":"2014","unstructured":"Imazio M, Brucato A, Adler Y. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2014;370:781.","journal-title":"N Engl J Med"},{"key":"1932_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ahj.2020.07.004","volume":"228","author":"AL Klein","year":"2020","unstructured":"Klein AL, Imazio M, Brucato A, et al. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1\u03b1 and interleukin-1\u03b2 trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81\u201390.","journal-title":"Am Heart J"},{"key":"1932_CR4","unstructured":"US.FDA. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125249s049lbl.pdf. Accessed 21 Aug 2024."},{"key":"1932_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjcard.2006.01.086","volume":"98","author":"A Brucato","year":"2006","unstructured":"Brucato A, Brambilla G, Moreo A, et al. Long-term outcomes in difficult-to-treat patients with recurrent pericarditis. Am J Cardiol. 2006;98:267\u201371.","journal-title":"Am J Cardiol"},{"key":"1932_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018950","volume":"10","author":"A Klein","year":"2021","unstructured":"Klein A, Cremer P, Kontzias A, et al. US database study of clinical burden and unmet need in recurrent pericarditis. J Am Heart Assoc. 2021;10: e18950.","journal-title":"J Am Heart Assoc"},{"key":"1932_CR7","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1007\/s12325-021-01868-7","volume":"38","author":"D Lin","year":"2021","unstructured":"Lin D, Lalibert\u00e9 F, Majeski C, et al. Disease and economic burden associated with recurrent pericarditis in a privately insured united states population. Adv Ther. 2021;38:5127\u201343.","journal-title":"Adv Ther"},{"key":"1932_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032516","volume":"13","author":"M Imazio","year":"2024","unstructured":"Imazio M, Klein AL, Brucato A, et al. sustained pericarditis recurrence risk reduction with long-term rilonacept. J Am Heart Assoc. 2024;13: e32516.","journal-title":"J Am Heart Assoc"},{"key":"1932_CR9","doi-asserted-by":"publisher","first-page":"7588085","DOI":"10.1155\/2023\/7588085","volume":"2023","author":"Z Chi","year":"2023","unstructured":"Chi Z, Bai X, Zhang Z. Adverse reaction signals mining of vonoprazan: a pharmacovigilance study based on FAERS. J Clin Pharm Ther. 2023;2023:7588085.","journal-title":"J Clin Pharm Ther"},{"key":"1932_CR10","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1177\/0962280215597579","volume":"26","author":"S Burgess","year":"2017","unstructured":"Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res. 2017;26:2333\u201355.","journal-title":"Stat Methods Med Res"},{"key":"1932_CR11","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"SG Davey","year":"2014","unstructured":"Davey SG, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89-98.","journal-title":"Hum Mol Genet"},{"key":"1932_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/EDE.0000000000000699","volume":"28","author":"SA Swanson","year":"2017","unstructured":"Swanson SA, Tiemeier H, Ikram MA, et al. Nature as a trialist?: Deconstructing the analogy between Mendelian randomization and randomized trials. Epidemiology. 2017;28:653\u20139.","journal-title":"Epidemiology"},{"key":"1932_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/aje\/kwj062","volume":"163","author":"D Nitsch","year":"2006","unstructured":"Nitsch D, Molokhia M, Smeeth L, et al. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol. 2006;163:397\u2013403.","journal-title":"Am J Epidemiol"},{"key":"1932_CR14","unstructured":"FDA. Food and Drug Administration Adverse Event Reporting System (FAERS). [Online]. Available at: https:\/\/open.fda.gov\/data\/faers\/. Accessed 21 Aug 2024."},{"key":"1932_CR15","unstructured":"Medical Dictionary for Regulatory Activities. Standardised MedDRA queries. https:\/\/www.meddra.org\/standardised-meddra-queries. Accessed 21 Aug 2024."},{"key":"1932_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, et al. Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC CardioOncol. 2019;1:172\u20138.","journal-title":"JACC CardioOncol"},{"key":"1932_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1932_CR18","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","volume":"15","author":"F Zou","year":"2024","unstructured":"Zou F, Cui Z, Lou S, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15:1338902.","journal-title":"Front Pharmacol"},{"key":"1932_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40264-016-0499-5","volume":"40","author":"ZA Trippe","year":"2017","unstructured":"Trippe ZA, Brendani B, Meier C, et al. Identification of substandard medicines via disproportionality analysis of individual case safety reports. Drug Saf. 2017;40:293\u2013303.","journal-title":"Drug Saf"},{"key":"1932_CR20","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMc2101978","volume":"384","author":"G Lazaros","year":"2021","unstructured":"Lazaros G, Tsioufis K, Vassilopoulos D. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med. 2021;384:1474\u20135.","journal-title":"N Engl J Med"},{"key":"1932_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/01.RES.0000078172.52740.9B","volume":"92","author":"RM Dewberry","year":"2003","unstructured":"Dewberry RM, Crossman DC, Francis SE. Interleukin-1 receptor antagonist (IL-1RN) genotype modulates the replicative capacity of human endothelial cells. Circ Res. 2003;92:1285\u20137.","journal-title":"Circ Res"},{"key":"1932_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamacardio.2023.4820","volume":"9","author":"RB Thorolfsdottir","year":"2024","unstructured":"Thorolfsdottir RB, Jonsdottir AB, Sveinbjornsson G, et al. Variants at the interleukin 1 gene locus and pericarditis. JAMA Cardiol. 2024;9:165\u201372.","journal-title":"JAMA Cardiol"},{"key":"1932_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13075-023-03122-7","volume":"25","author":"W Xie","year":"2023","unstructured":"Xie W, Li J, Du H, et al. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. Arthritis Res Ther. 2023;25:148.","journal-title":"Arthritis Res Ther"},{"key":"1932_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2022.6051","volume":"159","author":"SS Zhao","year":"2023","unstructured":"Zhao SS, Yiu Z, Barton A, et al. association of lipid-lowering drugs with risk of psoriasis: a Mendelian randomization study. JAMA Dermatol. 2023;159:275\u201380.","journal-title":"JAMA Dermatol"},{"key":"1932_CR25","doi-asserted-by":"publisher","first-page":"18097","DOI":"10.1038\/s41598-024-69180-2","volume":"14","author":"Q Niu","year":"2024","unstructured":"Niu Q, Zhang T, Mao R, et al. Genetic association of lipid and lipid-lowering drug target genes with atopic dermatitis: a drug target Mendelian randomization study. Sci Rep. 2024;14:18097.","journal-title":"Sci Rep"},{"key":"1932_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0167-9473(01)00097-4","volume":"40","author":"B Li","year":"2002","unstructured":"Li B, Martin EB. An approximation to the F distribution using the chi-square distribution. Comput Stat Data Anal. 2002;40:21\u20136.","journal-title":"Comput Stat Data Anal"},{"key":"1932_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/ije\/dyr036","volume":"40","author":"S Burgess","year":"2011","unstructured":"Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol. 2011;40:755\u201364.","journal-title":"Int J Epidemiol"},{"key":"1932_CR28","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/aje\/kwt084","volume":"178","author":"BL Pierce","year":"2013","unstructured":"Pierce BL, Burgess S. Efficient design for Mendelian randomization studies: subsample and 2-sample instrumental variable estimators. Am J Epidemiol. 2013;178:1177\u201384.","journal-title":"Am J Epidemiol"},{"key":"1932_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey SG, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512\u201325.","journal-title":"Int J Epidemiol"},{"key":"1932_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, Davey SG, Haycock PC, et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304\u201314.","journal-title":"Genet Epidemiol"},{"key":"1932_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32:377\u201389.","journal-title":"Eur J Epidemiol"},{"key":"1932_CR32","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1136\/hrt.2003.026120","volume":"90","author":"J Soler-Soler","year":"2004","unstructured":"Soler-Soler J, Sagrist\u00e0-Sauleda J, Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004;90:1364\u20138.","journal-title":"Heart"},{"key":"1932_CR33","doi-asserted-by":"publisher","first-page":"830","DOI":"10.2459\/JCM.0b013e3280110616","volume":"8","author":"M Imazio","year":"2007","unstructured":"Imazio M, Cecchi E, Ierna S, et al. CORP (COlchicine for Recurrent Pericarditis) and CORP-2 trials\u2013two randomized placebo-controlled trials evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of recurrent pericarditis: study design and rationale. J Cardiovasc Med (Hagerstown). 2007;8:830\u20134.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"1932_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4065\/mcp.2010.0046","volume":"85","author":"MH Khandaker","year":"2010","unstructured":"Khandaker MH, Espinosa RE, Nishimura RA, et al. Pericardial disease: diagnosis and management. Mayo Clin Proc. 2010;85:572\u201393.","journal-title":"Mayo Clin Proc"},{"key":"1932_CR35","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/0003-4819-155-7-201110040-00359","volume":"155","author":"M Imazio","year":"2011","unstructured":"Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409\u201314.","journal-title":"Ann Intern Med"},{"key":"1932_CR36","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/S0140-6736(13)62709-9","volume":"383","author":"M Imazio","year":"2014","unstructured":"Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232\u20137.","journal-title":"Lancet"},{"key":"1932_CR37","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European society of cardiology (ESC) endorsed by: the European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2015;36:2921\u201364.","journal-title":"Eur Heart J"},{"key":"1932_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jacc.2019.11.021","volume":"75","author":"JG Chiabrando","year":"2020","unstructured":"Chiabrando JG, Bonaventura A, Vecchi\u00e9 A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:76\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"1932_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11:32.","journal-title":"Biol Sex Differ"},{"key":"1932_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","volume":"44","author":"M Gandhi","year":"2004","unstructured":"Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499\u2013523.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1932_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2165\/00003495-199550020-00003","volume":"50","author":"RZ Harris","year":"1995","unstructured":"Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222\u201339.","journal-title":"Drugs"},{"key":"1932_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","volume":"35","author":"ST Ngo","year":"2014","unstructured":"Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35:347\u201369.","journal-title":"Front Neuroendocrinol"},{"key":"1932_CR43","doi-asserted-by":"publisher","first-page":"A377","DOI":"10.1016\/j.autrev.2011.11.001","volume":"11","author":"U Nussinovitch","year":"2012","unstructured":"Nussinovitch U, Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev. 2012;11:A377\u201385.","journal-title":"Autoimmun Rev"},{"key":"1932_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968815","volume":"13","author":"HW Grievink","year":"2022","unstructured":"Grievink HW, Smit V, Huisman BW, et al. Cardiovascular risk factors: the effects of ageing and smoking on the immune system, an observational clinical study. Front Immunol. 2022;13: 968815.","journal-title":"Front Immunol"},{"key":"1932_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa2027892","volume":"384","author":"AL Klein","year":"2021","unstructured":"Klein AL, Imazio M, Cremer P, et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. N Engl J Med. 2021;384:31\u201341.","journal-title":"N Engl J Med"},{"key":"1932_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068856","volume":"8","author":"S Berdot","year":"2013","unstructured":"Berdot S, Gillaizeau F, Caruba T, et al. Drug administration errors in hospital inpatients: a systematic review. PLoS ONE. 2013;8: e68856.","journal-title":"PLoS ONE"},{"key":"1932_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1345\/aph.1R147","volume":"47","author":"RN Keers","year":"2013","unstructured":"Keers RN, Williams SD, Cooke J, et al. Prevalence and nature of medication administration errors in health care settings: a systematic review of direct observational evidence. Ann Pharmacother. 2013;47:237\u201356.","journal-title":"Ann Pharmacother"},{"key":"1932_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122422","volume":"10","author":"BR Dalton","year":"2015","unstructured":"Dalton BR, Sabuda DM, Bresee LC, et al. Use of an electronic medication administration record (eMAR) for surveillance of medication omissions: results of a one year study of antimicrobials in the inpatient setting. PLoS ONE. 2015;10: e122422.","journal-title":"PLoS ONE"},{"key":"1932_CR49","first-page":"2195","volume":"351","author":"RA Lange","year":"2004","unstructured":"Lange RA, Hillis LD. Clinical practice. Acute pericarditis N Engl J Med. 2004;351:2195\u2013202.","journal-title":"Acute pericarditis N Engl J Med"},{"key":"1932_CR50","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cjco.2024.05.014","volume":"6","author":"A Brucato","year":"2024","unstructured":"Brucato A, Klein AL, Imazio M, et al. Reply to Albulushi et\u00a0al.-absence of pericarditis recurrence in rilonacept-treated patients with COVID-19 and SARS-CoV-2 vaccination: results from RHAPSODY long-term extension. CJC Open. 2024;6:1033\u20134.","journal-title":"CJC Open"},{"key":"1932_CR51","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","volume":"20","author":"MZ Tay","year":"2020","unstructured":"Tay MZ, Poh CM, R\u00e9nia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363\u201374.","journal-title":"Nat Rev Immunol"},{"key":"1932_CR52","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41590-020-0762-x","volume":"21","author":"JY Zhang","year":"2020","unstructured":"Zhang JY, Wang XM, Xing X, et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat Immunol. 2020;21:1107\u201318.","journal-title":"Nat Immunol"},{"key":"1932_CR53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s10156-010-0110-4","volume":"17","author":"M Jankovic","year":"2011","unstructured":"Jankovic M, Zmak L, Krajinovic V, et al. A fatal Mycobacterium chelonae infection in an immunosuppressed patient with systemic lupus erythematosus and concomitant Fahr\u2019s syndrome. J Infect Chemother. 2011;17:264\u20137.","journal-title":"J Infect Chemother"},{"key":"1932_CR54","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010595","volume":"7","author":"PE Lazzerini","year":"2018","unstructured":"Lazzerini PE, Capecchi PL, El-Sherif N, et al. Emerging arrhythmic risk of autoimmune and inflammatory cardiac channelopathies. J Am Heart Assoc. 2018;7: e10595.","journal-title":"J Am Heart Assoc"},{"key":"1932_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41577-018-0098-z","volume":"19","author":"PE Lazzerini","year":"2019","unstructured":"Lazzerini PE, Laghi-Pasini F, Boutjdir M, et al. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63\u20134.","journal-title":"Nat Rev Immunol"},{"key":"1932_CR56","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.120.008627","volume":"13","author":"PE Lazzerini","year":"2020","unstructured":"Lazzerini PE, Acampa M, Laghi-Pasini F, et al. Cardiac arrest risk during acute infections: systemic inflammation directly prolongs QTc interval via cytokine-mediated effects on potassium channel expression. Circ Arrhythm Electrophysiol. 2020;13: e8627.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1932_CR57","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022095","volume":"10","author":"PE Lazzerini","year":"2021","unstructured":"Lazzerini PE, Acampa M, Cupelli M, et al. Unravelling atrioventricular block risk in inflammatory diseases: systemic inflammation acutely delays atrioventricular conduction via a cytokine-mediated inhibition of connexin43 expression. J Am Heart Assoc. 2021;10: e22095.","journal-title":"J Am Heart Assoc"},{"key":"1932_CR58","doi-asserted-by":"publisher","first-page":"9763","DOI":"10.1038\/s41598-024-60239-8","volume":"14","author":"Y Li","year":"2024","unstructured":"Li Y, Gao G, Han Y, et al. Rho kinase inhibitor Y-27632 downregulates IL-1\u03b2 expression in mice with experimental autoimmune myocarditis. Sci Rep. 2024;14:9763.","journal-title":"Sci Rep"},{"key":"1932_CR59","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1365-2125.2011.03958.x","volume":"71","author":"EA Dubois","year":"2011","unstructured":"Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol. 2011;71:639\u201341.","journal-title":"Br J Clin Pharmacol"},{"key":"1932_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102763","volume":"20","author":"G Cavalli","year":"2021","unstructured":"Cavalli G, Colafrancesco S, Emmi G, et al. Interleukin 1\u03b1: a comprehensive review on the role of IL-1\u03b1 in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2021;20: 102763.","journal-title":"Autoimmun Rev"},{"key":"1932_CR61","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.alit.2023.02.005","volume":"72","author":"T Matsuda","year":"2023","unstructured":"Matsuda T, Takimoto-Ito R, Lipsker D, et al. Similarities and differences in autoinflammatory diseases with urticarial rash, cryopyrin-associated periodic syndrome and Schnitzler syndrome. Allergol Int. 2023;72:385\u201393.","journal-title":"Allergol Int"},{"key":"1932_CR62","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65:2486\u201396.","journal-title":"Arthritis Rheum"},{"key":"1932_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cyto.2015.03.022","volume":"74","author":"M Monteleone","year":"2015","unstructured":"Monteleone M, Stow JL, Schroder K. Mechanisms of unconventional secretion of IL-1 family cytokines. Cytokine. 2015;74:213\u20138.","journal-title":"Cytokine"},{"key":"1932_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155544","volume":"143","author":"J Geng","year":"2021","unstructured":"Geng J, Wang F, Huang Z, et al. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19. Cytokine. 2021;143: 155544.","journal-title":"Cytokine"},{"key":"1932_CR65","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.pcl.2012.03.014","volume":"59","author":"PJ Gowdie","year":"2012","unstructured":"Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am. 2012;59:301\u201327.","journal-title":"Pediatr Clin North Am"},{"key":"1932_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jcph.372","volume":"55","author":"J Autmizguine","year":"2015","unstructured":"Autmizguine J, Cohen-Wolkowiez M, Ilowite N. Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2015;55:39\u201344.","journal-title":"J Clin Pharmacol"},{"key":"1932_CR67","doi-asserted-by":"publisher","first-page":"1503713","DOI":"10.3389\/fphar.2024.1503713","volume":"15","author":"Y Hua","year":"2024","unstructured":"Hua Y, Li N, Lao J, et al. Machine learning models for coagulation dysfunction risk in inpatients administered \u03b2-lactam antibiotics. Front Pharmacol. 2024;15:1503713.","journal-title":"Front Pharmacol"},{"key":"1932_CR68","doi-asserted-by":"publisher","first-page":"1170987","DOI":"10.3389\/fphar.2023.1170987","volume":"14","author":"R Zhang","year":"2023","unstructured":"Zhang R, Gao L, Chen P, et al. Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study. Front Pharmacol. 2023;14:1170987.","journal-title":"Front Pharmacol"},{"key":"1932_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.924173","volume":"13","author":"R Zhang","year":"2022","unstructured":"Zhang R, Liu Y, Cao J, et al. The incidence and risk factors analysis of acute kidney injury in hospitalized patients received diuretics: a single-center retrospective study. Front Pharmacol. 2022;13: 924173.","journal-title":"Front Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s11096-026-02161-9","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000}}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01932-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:05:52Z","timestamp":1778681152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01932-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1932"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01932-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11096-026-02161-9","URL":"https:\/\/doi.org\/10.1007\/s11096-026-02161-9","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}